COMMUNIQUÉS West-GlobeNewswire

Pennant Reports Second Quarter 2025 Results
06/08/2025
Conference Call and Webcast scheduled for tomorrow, August 7, 2025 at 10:00 am MT EAGLE, Idaho, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
06/08/2025
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced it will provide a business update and report financial results for the [...]
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
06/08/2025
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity [...]
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
06/08/2025
Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph ® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE [...]
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
06/08/2025
2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted EBITDA ( 1 ) of [...]
Senseonics Holdings, Inc. Reports Second Quarter Financial Results
06/08/2025
Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, [...]
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
06/08/2025
– On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 [...]
Exagen Inc. to Participate in Third Quarter Investor Conferences
06/08/2025
CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor [...]
Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
06/08/2025
BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of [...]
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
06/08/2025
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY ® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth [...]
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
06/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class [...]
electroCore Announces Second Quarter 2025 Financial Results
06/08/2025
Net sales of $7.4 million increased 20% vs. Q2’2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, [...]
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
06/08/2025
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 [...]
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
06/08/2025
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% Yo Y, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% [...]
Certara Reports Second Quarter 2025 Financial Results
06/08/2025
Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the [...]
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
06/08/2025
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE [...]
DLH Reports Fiscal 2025 Third Quarter Results
06/08/2025
Robust Q3 Cash Flow Fuels Accelerated Debt Reduction; Strong Management of Operating Expenses Assures Margin Delivery ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company [...]
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
06/08/2025
Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 million Second Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, [...]
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
06/08/2025
Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trial Enrollment completed for rosnilimab Phase 2 ulcerative colitis trial; Top-line data through [...]

Pages